| Bioactivity | ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research[1]. |
| Target | Kd: 17±7 μM (EXOSC3-RNA interaction) |
| Invitro | ERD03 inhibits the binding of G-rich RNA and EXOSC3 with ~18% inhibition at 50 μM[1].ERD03 (50 μM; 5 days) causes significant spinal curvature and recapitulates PCH1B phenotype in development in zebrafish embryos[1].ERD03 (50 μM) induces a ~6-fold upregulation of ataxin1b mRNA and results in a minor accumulation of ataxin1a mRNA in embryos. ERD03 induces an atrophy of the zebrafish cerebellum and results in zebrafish cerebella half the size of control brains in DMSO[1]. |
| Name | ERD03 |
| CAS | 1377897-01-2 |
| Formula | C21H25NO3 |
| Molar Mass | 339.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liberty François-Moutal, et al. A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). ACS Chem Biol. 2018 Oct 19;13(10):3000-3010. |